Role of resection of the primary pancreatic neuroendocrine tumour only in patients with unresectable metastatic liver disease: A systematic review

Neuroendocrinology

Volumn 93, Issue 4, 2011, Pages 223-229

  Capurso, Gabriele ^a   Bettini, Rossella ^b   Rinzivillo, Maria ^a   Boninsegna, Letizia ^b,c   Fave, Gianfranco Delle ^a   Falconi, Massimo ^b,d  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SACRO CUORE DON CALABRIA HOSPITAL   (Italy)

^c UNIVERSITY OF VERONA   (Italy)

^d Chirurgia Generale B   (Italy)

Author keywords

Metastatic disease; Pancreatic neuroendocrine tumours; Surgery; Systematic review

Indexed keywords

ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; HUMAN; INOPERABLE CANCER; LIVER METASTASIS; MEDLINE; MORBIDITY; NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; PANCREAS ISLET CELL TUMOR; PANCREAS RESECTION; PANCREATIC NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

DISEASE-FREE SURVIVAL; HUMANS; LIVER NEOPLASMS; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 79959373617     PISSN: 00283835     EISSN: 14230194     Source Type: Journal    
DOI: 10.1159/000324770     Document Type: Article

References (29)

1. Fitzgerald TL, Hickner ZJ, Schmitz M, Kort EJ: Changing incidence of pancreatic neo-plasms. A 16-year review of statewide tumor registry. Pancreas 2008; 37: 134-138.
2. Yao JC, Eisner MP, Leary C, Dagohoy C, Phan A, Rashid A, Hassan M, Evans DB: Population-based study of islet cell carcino-ma. Ann Surg Oncol 2007; 14: 3492-3500. (Pubitemid 350160130)
3. Metz DC, Jensen RT: Gastrointestinal neu-roendocrine tumors: pancreatic endocrine tumors. Gastroenterology 2008; 135:1469-1492.
4. Panzuto F, Nasoni S, Falconi M, Corleto VD, Capurso G, Cassetta S, Di Fonzo M, Tornatore V, Milione M, Angeletti S, Cattaruzza MS, Ziparo V, Bordi C, Pederzoli P, Delle Fave G: Prognostic factors and survival in endocrine tumor patients: comparison be-tween gastrointestinal and pancreatic local-ization. Endocr Relat Cancer 2005; 12:1083-1092. (Pubitemid 41815799)
5. Chamberlain RS, Canes D, Brown KT, Saltz L, Jarnagin W, Fong Y, Blumgart LH: Hepatic neuroendocrine metastases: does inter-vention alter outcomes? J Am Coll Surg 2000; 190: 432-445. (Pubitemid 30181109)
6. Hodul PJ, Strosberg JR, Kvols LK: Aggressive surgical resection in the management of pancreatic neuroendocrine tumors: when is it indicated? Cancer Control 2008; 15: 314-321.
7. Wong RJ, DeCosse JJ: Cytoreductive surgery. Surg Gynecol Obstet 1990; 170:276-281. (Pubitemid 20139296)
8. Norton JA, Warren RS, Kelly MG, Zuraek MB, Jensen RT: Aggressive surgery for meta-static liver neuroendocrine tumors. Surgery 2003; 134: 1057-1065. (Pubitemid 38010754)
9. Sarmiento JM, Que FG, Grant CS, Thomp-son GB, Farnell MB, Nagorney DM: Concur-rent resections of pancreatic islet cell cancers with synchronous hepatic metastases: out-comes of an aggressive approach. Surgery 2002; 132: 976-983. (Pubitemid 36026944)
10. Scigliano S, Lebtahi R, Mairie F, Stievenart JL, Kianmanesh R, Sauvanet A, Vullierme MP, Couvelard A, Belghiti J, Ruszniewski P, Le Guludec D: Clinical and imaging follow-up after exhaustive liver resection of Endocrine metastases: a 15-year monocentric ex-perience. Endocr Relat Cancer 2009; 16: 977-990.
11. Bruzoni M, Parikh P, Celis R, Are C, Quan PL, Meza JL, Sasson AR: Management of the primary tumor in the patients with metastat-ic pancreatic neuroendocrine tumor: a con-temporary single-institution review. Am J Surg 2009; 197: 376-381.
12. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188. (Pubitemid 17189972)
13. Higgins JPT, Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21:1539-1558. (Pubitemid 34746062)
14. Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634. (Pubitemid 27387172)
15. Bettini R, Mantovani W, Boninsegna L, Crippa S, Capelli P, Bassi C, Scarpa A, Ped-erzoli P, Falconi M: Primary tumour resec-tion in metastatic nonfunctioning pancre-atic endocrine carcinomas. Dig Liver Dis 2009; 41:49-55.
16. Schurr PG, Strate T, Rese K, Kaifi JT, Reichelt U, Petri S, Kleinhans H, Yekebas EF, Izbicki JR: Aggressive surgery improves long-term survival in neuroendocrine pancreatic tu-mors. An institutional experience. Ann Surg 2007; 245:273-281. (Pubitemid 46148487)
17. Fischer L, Kleeff J, Esposito I, Hinz U, Zim-mermann A, Friess H, Büchler MW: Clinical outcome and long-term survival in 118 con-secutive patients with neuroendocrine tu-mours of the pancreas. Br J Surg 2008; 95: 627-635.
18. Nguyen SQ, Angel LP, Divino CM, Schluen-der S, Warner RR: Surgery in malignant pan-creatic neuroendocrine tumors. J Surg Oncol 2007; 96:397-403. (Pubitemid 47519445)
19. Solorzano CC, Lee JE, Pisters PW, Vauthey JN, Ayers JD, Jean ME, Gagel RF, Ajani JA, Wolff RA, Evans DB: Nonfunctioning islet cell carcinoma of the pancreas: survival re-sults in a contemporary series of 163 patients. Surgery 2001; 130: 1078-1085. (Pubitemid 34014578)
20. Madeira I, Voss TM, Denys A, Sauvanet A, Flejou JF, Vilgrain V, Belghiti J, Bernades P, Ruszniewski P: Prognostic factors in patients with endocrine tumors of the duodenopan-creatic area. Gut 1998; 43:422-427. (Pubitemid 28414926)
21. Pape UF, Berndt U, Müller-Nordhorn J, Böh-mig M, Roll S, Koch M, Willich SN, Wieden-mann B: Prognostic factors of long-term out-come in gastroenteropancreatic neuroEndocrine tumours. Endocr Relat Cancer 2008; 15:1083-1097.
22. Eriksson B, Klöppel G, Krenning E, Ahlman H, Plöckinger U, Wiedenmann B, Arnold R, Auernhammer C, Körner M, Rindi G, Wildi S, Frascati Consensus Conference Partici-pants: Consensus guidelines for the manage-ment of patients with digestive neuroEndocrine tumors-well-differentiated jejunal-ileal tumor/carcinoma. Neuroendocrinology 2008; 87:8-19. (Pubitemid 350308290)
23. Falconi M, Plockinger U, Kwekkeboom DJ, Manfredi R Korner M, Kvols L, Pape UF, Ricke J, Goretzki PE, Wildi S, Steinmuller T Oberg K, Scoazec JY, Frascati Consensus Conference; European Neuroendocrine Tu-mor Society: Well-differentiated pancreatic nonfunctioning tumours/carcinoma. Neu-roendocrinology 2006; 84: 196-211.
24. Hellman P, Lundström T, Ohrvall U, Eriks-son B, Skogseid B, Oberg K, Tiensuu Janson E, Akerström G: Effect of surgery on out-come of midgut carcinoid disease with lymph node and liver metastases. World J Surg 2002; 26: 991-997. (Pubitemid 36920298)
25. Ahmed A, Turner G, King B, Jones L, Culli-ford D, McCance D, Ardill J, Johnston BT, Poston G, Rees M, Buxton-Thomas M, Cap-lin M, Ramage JK: Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. Endocr Relat Cancer 2009; 16:885-894.
26. Gurusamy KS, Ramamoorthy R, Sharma D Davidson BR: Liver resection versus other treatments for neuroendocrine tumours in patients with resectable liver metastases. Co-chrane Database Syst Rev 2009; 2:CD007060.
27. Gurusamy KS, Pamecha V, Sharma D, Da-vidson BR: Palliative cytoreductive surgery versus other palliative treatments in patients with unresectable liver metastases from gas-tro-entero-pancreatic neuroendocrine tu-mours. Cochrane Database Syst Rev 2009; 1:CD007118.
28. Frilling A, Li J, Malamutmann E, Schmid KW, Bockisch A, Broelsch CE: Treatment of liver metastases from neuroendocrine tu-mours in relation to the extent of hepatic disease. Br J Surg 2009; 96:175-184.
29. Scarpa A, Mantovani W, Capelli P, Beghelli S, Boninsegna L, Bettini R, Panzuto F, Ped-erzoli P, Delle Fave G, Falconi M: Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clin-ically efficient prognostic stratification of patients. Mod Pathol 2010; 23: 824-833.